Key result
Prescription of QTc-prolonging medications in ICU patients resulted in a 48% incidence of QTc >500 ms or >60 ms increase, while beta-blockers were associated with reduced risk (OR 0.41).
Observational (n=200)
Nearly half of ICU patients prescribed QTc-prolonging medications develop significant QTc prolongation, with length of stay and baseline QTc as risk factors, while beta-blockers may offer a protective effect.
High QTc prolongation rates support vigilant ICU monitoring; leaves open beta-blocker protection pending prospective confirmation.
There is a paucity of information regarding QTc prolongation in critically ill patients. A prospective observational study was conducted to assess the incidence and predictors of QTc prolongation associated with medications in intensive care unit (ICU) patients. Consecutive adult patients prescribed prespecified QTc-prolonging medications were assessed for development of the combined incidence of QTc >500 ms at anytime and QTc increase >60 ms above baseline. Over 3 months, 200 consecutive patients (63 ± 18 years; 52% female; 73% Caucasian; baseline QTc 447.3 ± 51.5 ms) were evaluated. The primary end point occurred in 48% of the patients (QTc >500 ms 40%, QTc increase >60 ms 29%). The majority of patients experienced a QTc >470 or 450 ms (60.5%). Mean increase in QTc at 48 hours was 20 ± 35 ms. Upon multivariate analysis, length of stay [odds ratio 1.30, 95% confidence interval (1.15, 1.47)] and baseline QTc [1.01 (1.01, 1.02)] were associated with an increased risk for the primary end point, while beta-blockers [0.41 (0.20, 0.81)] were associated with a risk reduction. In conclusion, increased risk of proarrhythmia, as assessed by QTc prolongation, occurs in the majority of ICU patients when prescribed medications with electrophysiologic properties. Increased vigilance is warranted. The possible protective effect of beta-blockers requires confirmation.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2010) conducted an observational in Critically ill patients in the intensive care unit (n=200). QTc-prolonging medications was evaluated on Combined incidence of QTc >500 ms at anytime and QTc increase >60 ms above baseline. Prescription of QTc-prolonging medications in ICU patients resulted in a 48% incidence of QTc >500 ms or >60 ms increase, while beta-blockers were associated with reduced risk (OR 0.41).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: